Long-term follow-up study of patients with adrenal incidentalomas.
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The incidence of adrenal incidentalomas has sharply increased in recent decades and concurrent subtle endocrine abnormalities, or even subclinical conditions, have been identified. Nonetheless, data concerning possible changes in adrenal size and/or hormonal pattern during follow-up are still inadequate. OBJECTIVE: To evaluate long-term morphological and functional evolution of adrenal incidentalomas after initial diagnosis and to identify possible risk factors for hormonal hyperactivity and mass enlargement. PATIENTS: Sixty-four patients (34-79 years) were followed-up for 12-120 months (median 25.5 months). Initial computerized tomography scan showed a unilateral mass in 51 patients and bilateral lesions in 13 patients. Average mass diameter at diagnosis was 2.5+/-0.1 cm (range 1.0-4.0). Twelve patients had subclinical Cushing's syndrome, 41 had mild hormonal alterations, and 11 had normal adrenal function at baseline. All patients were investigated by morphological and functional evaluation 6 and 12 months after diagnosis, and then at 1-year intervals. RESULTS: During follow-up, a mass size increase >/=1 cm was observed in 13 patients, and 18 developed further subtle endocrine alterations. Cumulative risk of developing endocrine abnormalities was 17% at 1 year, 29% at 2 years, and 47% at 5 years. The risk was higher in the first 2 years of follow-up if the initial tumor diameter was >or=3 cm. Overall, cumulative risk of mass enlargement was 6% at 1 year, 14% at 2 years, and 29% at 5 years, and it was greater in patients with normal adrenal function than in those with subtle hormonal abnormalities (P<0.05). One female subject showed a mass enlargement after 6 months of follow-up and was eventually diagnosed with non-Hodgkin's lymphoma. CONCLUSIONS: Patients with an adrenal incidentaloma are at risk for tumor growth and development of hormonal alterations. The risk of adrenal malignancy, although not elevated, also indicates the need for long-term follow-up.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bulow et al. (31) reported 2% prevalence of Cushing's syndrome; Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
From The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. (2008) · cites this paper as [32]
In the citing paper
“However, if the lowest cutoffs were used [1.8 and 2.2 g/dl (50 and 60.6 nmol/liter), respectively], specificity decreased to 67-72%, whereas sensitivity increased to 75-100% (48 -62, 64 -67).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
In the citing paper
“Overall, in these studies, the different parameters showed a good specificity (90 -98%, using 1-mg DST) but, generally, a poor sensitivity (41-86% using ACTH levels).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
In the citing paper
“two studies suggested that in patients with an adrenal mass more than 2 cm in size, the estimated cumulative risk of developing SH may vary between 7 and 47% after 5 yr (50,52).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
Citations
Cites
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 855
Incidentally Discovered Adrenal Masses*
KLOOS, R. T., GROSS, M. D., FRANCIS, I. R., KOROBKIN, M., & SHAPIRO, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-460 · Cited by 828
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Young, W. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70122-5 · Cited by 415
Reincke, M. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.3.826 · Cited by 348 · cited 1×
“As previously reported (6, 9, 10 ), SCS was defined by the absence of signs or symptoms of hypercortisolism and by the presence of at least two of the following criteria: inadequate cortisol inhibition after 1 mg dexamethasone (cortisol levels $ 138 nmol/l), high or high – normal UFC excretion ($ 275 nmol/24 h), low o…”
BackgroundInfluentialSubclinical Cushing’s syndrome
Reincke, M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70115-8 · Cited by 285
Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1
Barzon, L., Scaroni, C., Sonino, N., Fallo, F., Paoletta, A., & Boscaro, M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5444 · Cited by 254 · cited 1×
“Recently, Barzon et al. (14) evaluated long-term clinical, hormonal, and morphological outcomes in patients with adrenal incidentalomas in order to obtain prognostic factors for disease progression. European Journal of Endocrinology (2002) 147 489–494 ISSN 0804-4643”
BackgroundSerendipitous adrenal masses: Prevalence, significance, and management
Abecassls, M., McLoughlin, M. J., Langer, B., & Kudlow, J. E. (1985) · The American Journal of Surgery · doi:10.1016/s0002-9610(85)80186-0 · Cited by 233
Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas)
Osella, G., Terzolo, M., Borretta, G., Magro, G., Alí, A., Piovesan, A., Paccotti, P., & Angeli, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989452 · Cited by 206
Subclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo, Osella, Alì, Borretta, Cesario, Paccotti, & Angeli, A. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00357.x · Cited by 198 · cited 1×
“However, in our retrospective study no patient showed an evolution to overt clinical hypercortisolism, in agreement with previous reports ( 11 , 15).”
ResultAbnormalities of endocrine function in patients with clinically silent adrenal masses.
Ambrosi, B., Peverelli, S., Passini, E., Re, T., Ferrario, R., Colombo, P., Sartorio, A., & Faglia, G. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1320422 · Cited by 136 · cited 2×
“As previously reported ( 6 , 9, 10), SCS was defined by the absence of signs or symptoms of hypercortisolism and by the presence of at least two of the following criteria: inadequate cortisol inhibition after 1 mg dexamethasone (cortisol levels $ 138 nmol/l), high or high – normal UFC excretion ($ 275 nmol/24 h), low…”
BackgroundMethodInfluentialSelf-citation
Cited by
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
The Incidentally Discovered Adrenal Mass
Young, W. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp065470 · Cited by 1,096
Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
“large and 3–4% may decrease in size (57, 63, 202, 467).”
Metadata
- Authors
- Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B.
- Affiliations
- University of Milan (IT)
- National Institutes of Health (US)
- Corresponding author
- Ambrosi, B
- ORCID
- Baccarelli, A
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10-01
- Volume
- 147
- Issue
- 4
- Pages
- 489-494
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2134170847
- Cited by
- 215
- References
- 21
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 13 · 2019: 14 · 2018: 7 · 2017: 11 · 2016: 10 · 2015: 11 · 2014: 13 · 2013: 5 · 2012: 14
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- adrenal incidentaloma, subclinical Cushing's syndrome, adrenal hyperfunction, tumor growth, long-term follow-up, risk factors, adrenal function, adrenal malignancy, non-Hodgkin lymphoma
- MeSH terms
- Adrenal Gland Neoplasms, Adult, Aged, Cushing Syndrome, Dexamethasone, Female, Follow-Up Studies, Glucocorticoids, Humans, Hydrocortisone, Male, Middle Aged, Retrospective Studies, Risk Factors, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term follow-up study of patients with adrenal incidentalomas. https://app.cochat.ai/papers/10.1530/eje.0.1470489
- The paper
- Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B. (2002). Long-term follow-up study of patients with adrenal incidentalomas. European Journal of Endocrinology. https://doi.org/10.1530/eje.0.1470489
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.